FindTrial
Sign In

comparison of 2 injectable medicines for management of hypertrophic scars

To determine the safety and efficacy of intralesional botulinum toxin injection in comparison to intralesional triamcinolone in management of keloids

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/07/044453
Enrollment
100
Registered
2022-07-28
Start date
Unknown
Completion date
Unknown
Last updated
2022-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L918- Other hypertrophic disorders of the skin

Interventions

Intervention1: intralesional botulinum toxin: 1 injection every 3 weeks, maximum of 3 Control Intervention1: intralesional triamcinolone injection: 1 injection every 3 weeks, maximum of 3 Control Inte

Sponsors

Military hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients willing to participate in the study. Patients of either sex with clinical features of keloid Patients in the age group of 18-60 years.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
reduction in size of keloidTimepoint: 12 weeks—

Secondary

MeasureTime frame
patient satisfaction scoreTimepoint: 12 weeks—

Countries

India

Contacts

Public ContactEeshaan ranjan

Ministry of Defence

eeshaan.ranjan@gmail.com8383058229

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026